TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05254860

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LPS Ventral Rectopexy
Description: Continuous Locked Suture vs Traditional 6-points suture for Laparoscopic Ventral Rectopexy to verify if the operative time of a standard laparoscopic ventral rectopexy for the treatment of severe rectal prolapse could be further reduced using continuous locked suture vs traditional 6-points suture for mesh fixation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LPS Ventral Rectopexy
Description: Continuous Locked Suture vs Traditional 6-points suture for Laparoscopic Ventral Rectopexy to verify if the operative time of a standard laparoscopic ventral rectopexy for the treatment of severe rectal prolapse could be further reduced using continuous locked suture vs traditional 6-points suture for mesh fixation
Study: NCT04088292

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase 20 Mg Powder for Solution for Injection Vial
Description: Low dose alteplase delivered IV or bu Ultrasound Assisted Thrombolysis device

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase 20 Mg Powder for Solution for Injection Vial
Description: Low dose alteplase delivered IV or bu Ultrasound Assisted Thrombolysis device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound assisted Thrombolysis
Description: Ultrasound assisted thrombolysis (USAT)
Study: NCT03776240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HD201
Description: Single-dose 6mg/kg body weight by 90 minute intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU-Herceptin
Description: Single-dose 6mg/kg body weight by 90 minute intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US-Herceptin
Description: Single-dose 6mg/kg body weight by 90 minute intravenous infusion
Study: NCT04082442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: 420 mg evolocumab.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Matching placebo.
Study: NCT02893436

Intervention type: PROCEDURE
Intervention: Surgery with tracheal intubation curarisation
Study: NCT04082689

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Assisted Infant Toilet Training
Description: The parents learn to sensitively respond to the child's routines and signals of elimination needs.The child's ability to convey the need for bowel and bladder evacuation is enhanced through responsive interaction so that a kind of assisted dryness is developed. The infant is held squatting over a potty or basin, while older children sit on the potty.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Assisted Infant Toilet Training
Description: The parents learn to sensitively respond to the child's routines and signals of elimination needs.The child's ability to convey the need for bowel and bladder evacuation is enhanced through responsive interaction so that a kind of assisted dryness is developed. The infant is held squatting over a potty or basin, while older children sit on the potty.
Study: NCT03368521

Intervention type: OTHER
Group type: OTHER
Intervention: Back pain screening test
Description: The care giver use the screening tool in order to score the back patient to three levels of risk. For each level of risk, one suggested type of care is provided; 1) simple advise; 2) physiotherapy; 3) multimodal rehabilitation. highest risk level includes multimodal intervention.
Study: NCT00558207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ 197
Description: 120 mg capsule administered twice daily for 240 mg total daily dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Description: 1000 mg/m2 administered as an intravenous infusion over 30 minutes once weekly for 4 weeks for the first 28 days (cycle). Each subsequent cycle will consist of 1000 mg/m2 administered as an intravenous infusion over 30 minutes once weekly for 3 weeks with no drug administered in the 4th week.
Study: NCT03172559

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Description: The recommended dose will be 30 Gy in 5 fractions. The treatment will be administered in 5 alternative days and will be individualized with the dose based on baseline liver function, effective liver volume irradiated and proximity to other normal tissues.
Study: NCT01029873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravenous infusions; 2 treatment courses; 2 treatment cycles for each course; 70mg/m2 on day 1 of cycle 1 for each course

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-801
Description: Intravenous infusions; cycle 1: day 3 and 5; cycle 2: day 1, 3 and 5; nine day rest period between cycles; seven day recovery period between courses~Stage 1: dose escalation (0.04 mg/kg, 0.06 mg/kg, 0.08 mg/kg)~Stage 2: dose expansion (dose at MTD)
Study: NCT02991859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) Dry Powder Inhaler
Description: Dry inhalation powder 25 mcg, 100 mcg, and 200 mcg per blister strip will be administered using ELLIPTA for both treatment periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) Dry Powder Inhaler
Description: Dry inhalation powder 25 mcg, 100 mcg, and 200 mcg per blister strip will be administered using ELLIPTA for both treatment periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) Dry Powder Inhaler
Description: Dry inhalation powder 25 mcg, 100 mcg, and 200 mcg per blister strip will be administered using ELLIPTA for both treatment periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) Dry Powder Inhaler
Description: Dry inhalation powder 25 mcg, 100 mcg, and 200 mcg per blister strip will be administered using ELLIPTA for both treatment periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) Dry Powder Inhaler
Description: Dry inhalation powder 25 mcg, 100 mcg, and 200 mcg per blister strip will be administered using ELLIPTA for both treatment periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) Dry Powder Inhaler
Description: Dry inhalation powder 25 mcg, 100 mcg, and 200 mcg per blister strip will be administered using ELLIPTA for both treatment periods
Study: NCT03706898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elpida®
Description: Elpida® capsules, 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elpida®
Description: Elpida® capsules, 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elpida®
Description: Elpida® capsules, 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: Dolutegravir, film-coated tablets, 50mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir, film-coated tablets, 400mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Daclatasvir, film-coated tablets, 60mg
Study: NCT01795820

Intervention type: DRUG
Group type: OTHER
Intervention: loading with Ticagrelor
Description: Patients allocated in the two study arms will receive the same anti platelet treatment, except for the administration of the loading dose, which will be only administered to patients allocated in Group 2

Intervention type: DRUG
Group type: OTHER
Intervention: no loading with Ticagrelor
Description: Patients allocated in the two study arms will receive the same anti platelet treatment, except for the administration of the loading dose, which will be only administered to patients allocated in Group 2.~In other words, patients randomized to this group (group 1) will not receive a loading dose of ticagrelor during the passage from clopidogrel to ticagrelor.
Study: NCT04314310

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenoxicam
Description: nonsteroidal anti-inflammatory drug (NSAID)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: equal volume of normal saline
Study: NCT03119207

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Naptime Protocol
Description: Between midnight and 4:00 every attempt will be made to limit staff entrance into the patient room.
Study: NCT02991859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) Dry Powder Inhaler
Description: Dry Inhalation powder 50 mcg, 100 mcg, 250 mcg, and 500 mcg per blister strip will be administered using DISKUS for both treatment periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) Dry Powder Inhaler
Description: Dry Inhalation powder 50 mcg, 100 mcg, 250 mcg, and 500 mcg per blister strip will be administered using DISKUS for both treatment periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) Dry Powder Inhaler
Description: Dry Inhalation powder 50 mcg, 100 mcg, 250 mcg, and 500 mcg per blister strip will be administered using DISKUS for both treatment periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) Dry Powder Inhaler
Description: Dry Inhalation powder 50 mcg, 100 mcg, 250 mcg, and 500 mcg per blister strip will be administered using DISKUS for both treatment periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) Dry Powder Inhaler
Description: Dry Inhalation powder 50 mcg, 100 mcg, 250 mcg, and 500 mcg per blister strip will be administered using DISKUS for both treatment periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) Dry Powder Inhaler
Description: Dry Inhalation powder 50 mcg, 100 mcg, 250 mcg, and 500 mcg per blister strip will be administered using DISKUS for both treatment periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) Turbuhaler
Description: Budesonide comprises white to off-white rounded granules, which disintegrate to a fine powder upon slight pressure, will be administered using Turbuhaler for both treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) Turbuhaler
Description: Budesonide comprises white to off-white rounded granules, which disintegrate to a fine powder upon slight pressure, will be administered using Turbuhaler for both treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) Turbuhaler
Description: Budesonide comprises white to off-white rounded granules, which disintegrate to a fine powder upon slight pressure, will be administered using Turbuhaler for both treatment periods.
Study: NCT03425227

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FRED EXERGAME
Description: biofeedback with physiological constants as follows: systolic blood pressure, diastolic blood pressure, heart rate and blood oxygen saturation
Study: NCT04088604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY01610 ( Irinotecan hydrochloride liposome injection )
Description: Part1-Dose Escalation and Part1-Dose Extension : subjects take LY01610;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY01610 ( Irinotecan hydrochloride liposome injection )
Description: Part1-Dose Escalation and Part1-Dose Extension : subjects take LY01610;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY01610 ( Irinotecan hydrochloride liposome injection ) with 5-Fu（Fluorouracil Injection）
Description: Part2-Dose Escalation and Part2-Dose Extension : subjects take LY01610 with 5-Fu;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY01610 ( Irinotecan hydrochloride liposome injection ) with 5-Fu（Fluorouracil Injection）
Description: Part2-Dose Escalation and Part2-Dose Extension : subjects take LY01610 with 5-Fu;

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan Hydrochloride Injection（CAMPTO®）
Description: Irinotecan Hydrochloride Injection（CAMPTO®） pharmacokinetics comparative study
Study: NCT00560378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment 0.1%
Description: Topical
Study: NCT05342532

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: 1 g

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: 1 g

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: 40 mg. Patients were asked to take omeprazole one hour prior to food intake, while antibiotics were taken after meals.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: 40 mg. Patients were asked to take omeprazole one hour prior to food intake, while antibiotics were taken after meals.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: 500 mg twice daily
Study: NCT04150406

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flexofytol
Description: Curcuma extract

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT02991859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) Turbuhaler
Description: Budesonide comprises white to off-white rounded granules, which disintegrate to a fine powder upon slight pressure, will be administered using Turbuhaler for both treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) Turbuhaler
Description: Budesonide comprises white to off-white rounded granules, which disintegrate to a fine powder upon slight pressure, will be administered using Turbuhaler for both treatment periods.
Study: NCT02948218

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture treatment
Description: Acupuncture treatment will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture treatment
Description: Acupuncture treatment will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture treatment
Description: Acupuncture treatment will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture treatment
Description: Acupuncture treatment will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
Study: NCT02063971

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soothing (formulation number: F#1048-082) and antiaging creams (F#841-020 and F#1374-002)
Study: NCT04255927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coated Vicryl plus
Description: Vicryl plus (Coated Polyglactin 910 with Triclosan)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coated vicryl
Description: Vicryl (Coated Polyglactin 910 without Triclosan)
Study: NCT00558571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 low dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to BI 10773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 medium dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 high dose
Study: NCT02325791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suptavumab 30 mg/kg
Description: Participants received single dose of suptavumab 30 milligram per kilogram (mg/kg) intramuscularly (IM) on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Matched to Suptavumab
Description: Participants received 2 IM doses of placebo matched to suptavumab: the first dose on Day 1 and the second dose on Day 57.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suptavumab 30 mg/kg- 1 Dose
Description: Participants received single dose of suptavumab 30 mg/kg IM on Day 1 and single dose of placebo matched to suptavumab on Day 57.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suptavumab 30 mg/kg - 2 Doses
Description: Participants received 2 doses of suptavumab 30 mg/kg IM: the first dose on Day 1 and the second dose on Day 57.
Study: NCT03862040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefiderocol
Description: Administered intravenously, at a dosage determined based on renal function.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care Antibiotic
Description: Standard of care antibiotic treatment for pneumonia
Study: NCT03665831

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brainsway H1-Coil Deep TMS System
Description: Deep Transcranial Magnetic Stimulation (dTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel dTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions. dTMS will be administered daily for 4 consecutive weeks.
Study: NCT04094077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGuIX
Description: 2 IV injections (100 mg/Kg/injection) at day 4 and day 8 + Strereotactic Radiation from day 8 to day 15 as per standard practice.
Study: NCT02991859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) Turbuhaler
Description: Budesonide comprises white to off-white rounded granules, which disintegrate to a fine powder upon slight pressure, will be administered using Turbuhaler for both treatment periods.
Study: NCT03596632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenebrutinib
Description: 200-mg (100 µCi) oral solution 14C/12C\]-fenebrutinib
Study: NCT01028378

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T-CAT topography-guided LASIK treatment with the Allegretto Wave Eye-Q 400 Hz Excimer Laser
Study: NCT01763242

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EMAN
Description: See details on ESA Synchronization and Dosing in Detailed Description Above
Study: NCT00527670

Intervention type: PROCEDURE
Intervention: Normal Controls
Description: The control group will have small slivers of tissue removed from the skin and abdomen during surgery to compare genomic information.

Intervention type: PROCEDURE
Intervention: Recurrent Hernia
Description: This group will have small slivers of tissue removed from the skin and abdomen during hernia repair surgery to find genetic proof of hernias being inherited.
Study: NCT01298193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Efficacy phase (second cycle)
Study: NCT01216007

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: In the TIVA group, IV access will be obtained as per BCCH routine, with caregiver present. 2% lidocaine 1 mg/kg will be administered via IV to prevent venous pain before induction of anaesthesia with propofol, as per BCCH standard. Induction of anaesthesia will be achieved with an IV bolus of propofol 5 mg/kg and remifentanil 2.5 mcg/kg. Anaesthesia will be maintained with an infusion of propofol 200-400 mcg/kg/min and remifentanil 0.1-0.2 mcg/kg/min. Once the subject is under general anaesthesia, the anaesthesiologist will place a second IV cannula, specifically for the collection of blood samples. This cannula will not be in the same limb as the propofol infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane
Description: In the volatile anaesthesia group, induction of anaesthesia will be achieved with inhalation of sevoflurane (5-8% in O2/air). Maintenance of anaesthesia will continue with a volatile agent of the anaesthesiologist's choice.
Study: NCT05811650

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Oral Health Counseling and promotion
Description: The intervention was cluster randomized control trial in design. We select six schools for the intervention group and six schools for the control group. Follow-up of the intervention was done after six months of baseline. Impact of the intervention was assessed among the same participants who enrolled in the baseline. The interventions were done in every three months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral Health Counseling and promotion
Description: The intervention was cluster randomized control trial in design. We select six schools for the intervention group and six schools for the control group. Follow-up of the intervention was done after six months of baseline. Impact of the intervention was assessed among the same participants who enrolled in the baseline. The interventions were done in every three months.
Study: NCT02448836

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dTMS H-coil system:magstim stimulator rapid2,BrainswayH1coil
Description: Patients will undergo 8 sessions of dTMS treatment for two weeks (4 sessions every week).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham: dTMS H-coil system:magstim stimulator rapid2,BrainswayH1coil
Description: Patients will undergo 8 sessions of Sham dTMS treatment for two weeks (4 sessions every week).
Study: NCT04971616

Intervention type: OTHER
Intervention: Demographic data and range of motion.
Description: The body parameters (BMI, age, gender), daily activities (daily steps, sedentary), work and rest time (sleep time, quality) were collected through wearable devices. The range of motion of neck and waist was collected through hand-held devices.
Study: NCT02171364

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual ablation in based 3D CT of patient who diagnosed AF

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional ablation based on physician's personal experience
Study: NCT03751540

Intervention type: PROCEDURE
Intervention: ostap
Description: this block is performed under general anesthesia in this patients for postoperative analgesia.

Intervention type: PROCEDURE
Intervention: SIPB plus rectus sheath block
Description: this block is performed under general anesthesia in this patients for postoperative analgesia.